AR131815A1 - Conjugados de enlace autoestabilizantes - Google Patents
Conjugados de enlace autoestabilizantesInfo
- Publication number
- AR131815A1 AR131815A1 ARP240100295A ARP240100295A AR131815A1 AR 131815 A1 AR131815 A1 AR 131815A1 AR P240100295 A ARP240100295 A AR P240100295A AR P240100295 A ARP240100295 A AR P240100295A AR 131815 A1 AR131815 A1 AR 131815A1
- Authority
- AR
- Argentina
- Prior art keywords
- self
- antibody
- drug conjugate
- conjugates
- stabilizing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación proporciona plataformas de conjugado anticuerpo-fármaco que comprenden un componente de conjunto enlazador autoestabilizante, y conjugados de anticuerpo-fármaco que comprenden enlazadores-cargas útiles derivadas de la plataforma y anticuerpos o fragmentos de unión a antígeno de los mismos. En algunas formas de realización, un conjugado de anticuerpo-fármaco es de la siguiente fórmula: (1), o una sal, tautómero, solvato o estereoisómero farmacéuticamente aceptable del mismo, en donde los valores para las variables (por ejemplo, BA, RG, R¹ᵃ, R¹ᵇ, r, RS, R²ᵃ, R²ᵇ, s, R⁴, R³ᵃ, R³ᵇ, t, RE, A, a, W, w, Y, y, PA, x) son como se describe en el presente documento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023075152 | 2023-02-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR131815A1 true AR131815A1 (es) | 2025-05-07 |
Family
ID=90361924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100295A AR131815A1 (es) | 2023-02-09 | 2024-02-07 | Conjugados de enlace autoestabilizantes |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250352659A1 (es) |
| EP (1) | EP4661913A1 (es) |
| JP (1) | JP2026508145A (es) |
| KR (1) | KR20250145079A (es) |
| CN (1) | CN120641134A (es) |
| AR (1) | AR131815A1 (es) |
| AU (1) | AU2024218327A1 (es) |
| CL (1) | CL2025002361A1 (es) |
| CO (1) | CO2025011949A2 (es) |
| IL (1) | IL322569A (es) |
| MX (1) | MX2025009350A (es) |
| TW (1) | TW202434311A (es) |
| WO (1) | WO2024165045A1 (es) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ES2369542T3 (es) | 2002-07-31 | 2011-12-01 | Seattle Genetics, Inc. | Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa. |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| BRPI0510909A2 (pt) | 2004-05-19 | 2008-12-16 | Medarex Inc | composto de ligaÇço fÁrmaco-ligante citotàxico, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula e mÉtodo para retardar ou interromper o crescimento de tumor |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| ES2708763T3 (es) | 2005-07-07 | 2019-04-11 | Seattle Genetics Inc | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| EA016577B1 (ru) | 2005-09-26 | 2012-06-29 | Медарекс, Инк. | Конъюгаты антитело-лекарство и их применение |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| NZ588884A (en) | 2008-04-30 | 2013-05-31 | Immunogen Inc | Cross-linkers and their uses |
| CN104822656B (zh) * | 2012-05-15 | 2018-05-01 | 西雅图基因公司 | 自稳定接头偶联物 |
| US10195288B2 (en) | 2012-10-11 | 2019-02-05 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| SMT202100146T1 (it) | 2014-04-30 | 2021-05-07 | Pfizer | Coniugati di anticorpo anti-ptk7-farmaco |
| EP3700577A1 (en) | 2017-10-23 | 2020-09-02 | Mablink Bioscience | Ligand-drug-conjugate comprising a single molecular weight polysarcosine |
| CN111936169A (zh) * | 2018-04-06 | 2020-11-13 | 西雅图遗传学公司 | 喜树碱肽缀合物 |
| TWI920652B (zh) * | 2018-06-07 | 2026-04-01 | 美商思進公司 | 喜樹鹼結合物 |
| CN116615250A (zh) | 2020-11-12 | 2023-08-18 | 第一三共株式会社 | 通过施用抗b7-h3抗体-药物缀合物的间皮瘤治疗 |
| IL305886A (en) * | 2021-03-18 | 2023-11-01 | Seagen Inc | Selective release of drugs from internalized conjugates of biologically active compounds |
| JP7892050B2 (ja) * | 2021-07-30 | 2026-07-17 | シャンハイ フダン-チャンジャン バイオ-ファーマシューティカル カンパニー リミテッド | 抗dll3抗体とその製造方法、その薬物複合体及び使用 |
-
2024
- 2024-02-07 KR KR1020257030037A patent/KR20250145079A/ko active Pending
- 2024-02-07 TW TW113105114A patent/TW202434311A/zh unknown
- 2024-02-07 AR ARP240100295A patent/AR131815A1/es unknown
- 2024-02-07 WO PCT/CN2024/076657 patent/WO2024165045A1/en not_active Ceased
- 2024-02-07 AU AU2024218327A patent/AU2024218327A1/en active Pending
- 2024-02-07 JP JP2025546002A patent/JP2026508145A/ja active Pending
- 2024-02-07 CN CN202480011335.5A patent/CN120641134A/zh active Pending
- 2024-02-07 EP EP24709639.9A patent/EP4661913A1/en active Pending
- 2024-02-07 IL IL322569A patent/IL322569A/en unknown
-
2025
- 2025-08-06 US US19/292,082 patent/US20250352659A1/en active Pending
- 2025-08-07 CL CL2025002361A patent/CL2025002361A1/es unknown
- 2025-08-08 MX MX2025009350A patent/MX2025009350A/es unknown
- 2025-09-03 CO CONC2025/0011949A patent/CO2025011949A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024165045A1 (en) | 2024-08-15 |
| AU2024218327A1 (en) | 2025-09-25 |
| IL322569A (en) | 2025-10-01 |
| TW202434311A (zh) | 2024-09-01 |
| CN120641134A (zh) | 2025-09-12 |
| KR20250145079A (ko) | 2025-10-13 |
| MX2025009350A (es) | 2025-09-02 |
| EP4661913A1 (en) | 2025-12-17 |
| JP2026508145A (ja) | 2026-03-10 |
| US20250352659A1 (en) | 2025-11-20 |
| CL2025002361A1 (es) | 2025-12-05 |
| CO2025011949A2 (es) | 2025-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024007498A (es) | Compuesto de camptotecina y conjuado del mismo. | |
| ECSP20014523A (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco | |
| MX2021011394A (es) | Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico. | |
| MX2026001061A (es) | Inhibidores de la fosfatidilinositol 3-cinasa (pi3k) | |
| CO2018010919A2 (es) | Moleculas de unión b7-h3 novedosas, conjugados anticuerpo - fármaco de los mismos y métodos de uso de los mismos | |
| CO6670522A2 (es) | Conjugados de anticuerpos multifuncionales de anticuerpos anti-igf1r, derivados de los mismos y composiciones que los contienen | |
| CO2024006160A2 (es) | Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este | |
| CY1115289T1 (el) | Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη | |
| UY37457A (es) | Compuestos de anticuerpos acoplados de tirosina-tirosina cíclica como moduladores de receptores del neuropeptido y | |
| AR132196A1 (es) | Conjugado bioactivo, método de preparación del mismo y uso del mismo | |
| MX2021010003A (es) | Anticuerpos anti-mertk de alta afinidad y usos de los mismos. | |
| AR067838A1 (es) | Compuestos pirrolicos, composiciones farmaceuticas que los contienen y usos | |
| AR125473A1 (es) | Conjugados de anticuerpo anti-c-met y fármaco | |
| CR20250060A (es) | Anticuerpos anti monometil auristatina y fragmentos de anticuerpos. | |
| MX2021006430A (es) | Composiciones farmacéuticas que comprenden conjugados de fármaco-anticuerpo anti-191p4d12 y métodos de uso de las mismas. | |
| BR112021025720A2 (pt) | Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados | |
| AR132698A1 (es) | DERIVADOS ESPIRO COMO INHIBIDORES DE LA HELICASA TIPO RecQ DEL SÍNDROME DE WERNER (WRN) | |
| PE20250159A1 (es) | Conjugados de neodegradador-anticuerpo anti-cd33 | |
| CL2022000319A1 (es) | Derivados de amidas híbridas de anfotericina b | |
| CL2025001214A1 (es) | Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos | |
| MX2024010334A (es) | Composicion farmaceutica que comprende anticuerpo biespecifico anti-ctla4-anti-pd-1 y chiauranib. | |
| MX2024012471A (es) | Inhibidores de cinasas dependientes de ciclina 9 (cdk9) | |
| CO2025009064A2 (es) | Conjugado anticuerpo-fármaco que se une a her3 | |
| UY40495A (es) | 1,3,5-triazinas 2,4,6-trisustituidas como moduladores de cx3cr1 | |
| CR20240489A (es) | Agentes aglutinantes 5t4 y usos de los mismos |